Bluebird Bio Inc. (NASDAQ:BLUE) shares were down 5% on Tuesday . The stock traded as low as $53.27 and last traded at $53.51, with a volume of 496,886 shares. The stock had previously closed at $56.30.

Several research analysts have recently weighed in on BLUE shares. Vetr lowered shares of Bluebird Bio from a “strong-buy” rating to a “buy” rating and set a $55.90 price objective on the stock. in a research note on Wednesday, April 6th. Goldman Sachs Group Inc. restated a “buy” rating and set a $149.00 price objective on shares of Bluebird Bio in a research note on Monday, April 11th. BTIG Research restated a “buy” rating and set a $72.00 price objective on shares of Bluebird Bio in a research note on Wednesday, April 20th. Maxim Group restated a “buy” rating and set a $105.00 price objective on shares of Bluebird Bio in a research note on Wednesday, April 20th. Finally, Zacks Investment Research lowered shares of Bluebird Bio from a “hold” rating to a “sell” rating in a research note on Monday, May 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $94.84.

The firm has a 50 day moving average price of $47.17 and a 200 day moving average price of $45.82. The stock’s market capitalization is $1.99 billion.

Bluebird Bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $2.01 million. The firm’s revenue for the quarter was down 68.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.57) EPS. On average, analysts forecast that Bluebird Bio Inc. will post ($5.91) earnings per share for the current year.

In other Bluebird Bio news, insider David Davidson sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 15th. The shares were sold at an average price of $40.11, for a total transaction of $40,110.00. Following the sale, the insider now owns 10,600 shares in the company, valued at approximately $425,166. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Philip D. Gregory sold 2,931 shares of the firm’s stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $39.52, for a total transaction of $115,833.12. Following the sale, the insider now owns 30,069 shares in the company, valued at approximately $1,188,326.88. The disclosure for this sale can be found here.

Other large investors have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its stake in Bluebird Bio by 6.0% in the fourth quarter. Rhumbline Advisers now owns 35,855 shares of the company’s stock worth $2,303,000 after buying an additional 2,023 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Bluebird Bio by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 74,831 shares of the company’s stock worth $4,806,000 after buying an additional 4,454 shares during the last quarter. California Public Employees Retirement System boosted its stake in Bluebird Bio by 157.2% in the fourth quarter. California Public Employees Retirement System now owns 94,400 shares of the company’s stock worth $6,062,000 after buying an additional 57,700 shares during the last quarter. Marshall Wace LLP boosted its stake in Bluebird Bio by 374.8% in the fourth quarter. Marshall Wace LLP now owns 168,427 shares of the company’s stock worth $10,816,000 after buying an additional 132,956 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its stake in Bluebird Bio by 27.8% in the fourth quarter. New York State Common Retirement Fund now owns 171,022 shares of the company’s stock worth $10,983,000 after buying an additional 37,178 shares during the last quarter.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.